Lynavoy
Lynavoy ingredients
| Active ingredient | Strength |
|---|---|
| Linerixibat | 40 mg/1 |
What Lynavoy is used for
The FDA lists the approved uses on the official label (below). In the EU, Linerixibat is approved as Lynavoy for:
Lynavoy is indicated for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Lynavoy
- Generic name
- Linerixibat
- Made by
- Intercept Pharmaceuticals Inc
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Ileal Bile Acid Transporter Inhibitor
- FDA approval
- New drug application (NDA) NDA220295
- On the US market since
- 2026
Official information
- Lynavoy prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Linerixibat)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lynavoy?
Lynavoy (Linerixibat) is a specialist medicine made by Intercept Pharmaceuticals Inc, approved by the US FDA.
What are the ingredients of Lynavoy?
Lynavoy contains Linerixibat (40 mg/1).
Is Lynavoy approved in Europe?
The same active substance is approved in the EU as Lynavoy.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA